✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Sexual Health · Provider Directory

Sexual Health Peptides & Therapies

Released: Last reviewed:

Sexual health peptides target melanocortin (PT-141 / bremelanotide) and oxytocin pathways for desire and arousal disorders, and GnRH-receptor agonism (gonadorelin, kisspeptin) for endogenous hormone modulation. PT-141 is FDA-approved as Vyleesi for HSDD in premenopausal women; the rest are off-label or compounded.

5 peptides covered v4.1 methodology All 50 states + DC
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.

Peptides in this category

Top telehealth providers for sexual health

See the full provider directory for profiles, dated prices and scores.

Editorial team

Researched by Dr. Parmis (Medical Researcher, Western University of Health Sciences); medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC).

Related categories

Key facts, checked November 20, 2026

Sexual-health peptides on this site include PT-141, oxytocin, kisspeptin and gonadorelin. Kisspeptin-10 is in FDA’s 503A Category 2, substances that may present significant safety risks, per FDA’s 503A bulk-substance category lists. None of the peptides in this category is covered by the draft HHS draft peptide policy (91 FR 68526) as reported. Telehealth clinics that sell them should name the pharmacy and the legal basis for compounding; each peptide page carries a dated FDA status notice from our October 15, 2026 check, re-confirmed for the HHS change on November 20, 2026.